KTTA — Pasithea Therapeutics Corp.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1841330 ·
Last close
$0.49
Market Cap
$16.45M
52W High
$0.96
52W Low
$0.47
ADV30
1,321,971
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -4,876,644 | -2,869,482 | 56,354,901 | 50,400,377 | 1,542,451 |
| Dec 2025 | 0 | — | -10,256,162 | -10,110,868 | 60,240,070 | 55,158,939 | 5,020,832 |
| Sep 2025 | 0 | — | -3,110,055 | -3,037,420 | 13,630,664 | 4,122,953 | 1,423,982 |
| Jun 2025 | 0 | — | -3,810,899 | -3,716,157 | 17,009,142 | 7,217,052 | 1,830,697 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-16,942,953
Investing CF
$0
Financing CF
$62,045,244
CapEx
—
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-2.80
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-72,879,943
Inventory
—
Receivables
$0
ST Investments
—
EBIT TTM
$-22,053,760
Pretax Income TTM
$-19,733,927
Interest Exp TTM
—
Analysts
1
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -20,857,295 | -20,427,683 | 60,240,070 | 5,020,832 | — | -15,211,490 |
| Dec 2024 | 0 | -14,249,962 | -13,904,584 | 16,064,719 | 1,282,043 | — | -13,923,438 |
| Dec 2023 | 0 | -15,979,361 | -15,961,658 | 26,116,858 | 2,718,406 | — | -13,425,411 |
| Dec 2022 | 0 | -12,588,971 | -13,936,452 | 45,180,089 | 2,681,841 | — | -13,691,158 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.01
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CYCN | Cyclerion Therapeutics, Inc. | $16.61M | $3.84 | — |
| MBRX | Moleculin Biotech, Inc. | $16.11M | $2.28 | — |
| LEXX | Lexaria Bioscience Corp. | $16.03M | $0.65 | — |
| CTXR | Citius Pharmaceuticals, Inc. | $16.00M | $0.58 | — |
| BIVI | BIOVIE INC. | $17.12M | $2.27 | — |
News headlines (Yahoo Finance, 1h cache)
Pasithea Therapeutics Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit
2026-07-08 11:02 · Yahoo
Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-Term Safety and Tolerability, and Durable Clinical Activity in MEK/BRAF-Pretreated Patients, plus
2026-06-30 11:00 · Yahoo
Pasithea Therapeutics Announces Amendments to Clinical Study Protocol for Phase 1/1B NF1 Clinical Trial
2026-06-16 11:00 · Yahoo
Pasithea Therapeutics Announces Exhibit at Children’s Tumor Foundation 2026 NF Conference
2026-06-15 11:02 · Yahoo
Pasithea Therapeutics (KTTA) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
2026-06-10 13:55 · Yahoo
Pasithea Therapeutics Announces Orphan Drug Designation by FDA of PAS-004 for Treatment of Amyotrophic Lateral Sclerosis (ALS)
2026-06-02 11:02 · Yahoo
Pasithea Therapeutics Announces Appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer
2026-05-04 11:01 · Yahoo
Is Pasithea Therapeutics (NASDAQ:KTTA) In A Good Position To Deliver On Growth Plans?
2026-05-03 12:59 · Yahoo
Pasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation (RPDD) by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1)
2026-04-20 11:01 · Yahoo
Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant Morbidity
2026-04-01 11:01 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.